Latest On Hutchison China MediTech Limited (HCM):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-07 15:16 EST | News | Our Update On Hutchmed China's Progress | N/A |  |
| 2023-04-04 07:51 EST | News | Hutchmed starts registration phase for cancer trials after talks with Chinese regulator | N/A | |
| 2023-03-01 05:18 EST | News | HUTCHMED (China) Limited (HCM) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-28 14:18 EST | News | Hutchison China MediTech reports mixed Q4 earnings; initiates FY23 outlook | N/A | |
| 2023-02-06 13:02 EST | News | Hutchmed: We Explore Pharma In China | N/A | |
| 2023-01-23 10:40 EST | News | Takeda to acquire rights to Hutchmed's cancer drug fruquintinib for $400M upfront | N/A | |
| 2023-01-19 14:03 EST | News | AstraZeneca, Hutchmed's Orpathys included in China's national reimbursement drug list | N/A | |
| 2023-01-03 10:40 EST | News | Hutchmed completes enrollment in phase 3 trial of blood disorder drug | N/A | |
| 2022-12-16 15:11 EST | News | Chinese pharmas and biotechs risk of delisting averted as US regulators review audits | N/A | |
| 2022-12-02 16:23 EST | News | HUTCHMED (HCM) Investor Presentation - Slideshow | N/A | |
| 2022-11-15 12:46 EST | News | Hutchmed to focus on late-stage drugs, deprioritize early-phase programs | N/A | |
| 2022-11-14 20:02 EST | News | Hutchmed stock rises 15% as fruquintinib meets one main goal in gastric cancer trial | N/A | |
| 2022-10-10 07:14 EST | News | Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder | N/A | |
| 2022-09-16 20:45 EST | News | HUTCHMED (China) (HCM) Presents at ESMO Congress 2022 | N/A | |
| 2022-08-09 15:31 EST | News | Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004 | N/A | |
| 2022-08-08 15:15 EST | News | Hutchmed fruquintinib improves survival, meets main goal of colorectal cancer study | N/A | |
| 2022-08-08 15:14 EST | News | AstraZeneca, Hutchmed savolitinib/ Tagrisso combo shows response in some lung cancer patients | N/A | |
| 2022-08-03 15:14 EST | News | HUTCHMED (China) Limited (HCM) CEO Weiguo Su On Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-01 20:06 EST | News | Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype | N/A | |
| 2022-08-01 20:06 EST | News | Hutchison China MediTech GAAP EPADS of -$0.96, revenue of $202.05M | N/A | |
| 2022-08-01 20:06 EST | News | HUTCHMED (China) Limited 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-08-01 20:06 EST | News | HUTCHMED (China) Limited (HCM) CEO Christian Hogg on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-07-15 07:16 EST | News | Hutchmed begins dosing in early-stage study of cancer drug HMPL-A83 | N/A | |
| 2022-07-06 16:07 EST | News | Hutchmed, Inmagene begin dosing in early-stage study of IMG-007 for eczema | N/A | |
| 2022-06-03 12:46 EST | News | HUTCHMED (China) (HCM) Investor Presentation - Slideshow | N/A | |
| 2022-06-01 08:56 EST | News | Hutchmed, Epizyme cancer drug Tazverik gets China's Hainan province health regulator nod | N/A | |
| 2022-05-02 13:25 EST | News | Hutchmed stock falls as FDA rejects surufatinib to treat neuroendocrine tumors | N/A | |
| 2022-03-16 20:52 EST | News | U.S.-listed Chinese pharma stocks are on the rise | N/A | |
| 2022-03-07 13:28 EST | News | Hutchmed gets $15M from AstraZeneca as part of Orpathys drug program in lung cancer | N/A | |
| 2022-03-04 16:18 EST | News | HUTCHMED (China) Limited 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-03 22:44 EST | News | Hutchison China MediTech GAAP EPS of -$0.25 beats by $1.54, revenue of $356.1M beats by $17.33M | N/A | |
| 2022-03-03 22:44 EST | News | Hutchmed CEO Christian Hogg retires | N/A | |
| 2022-03-03 22:44 EST | News | HUTCHMED (China) Limited (HCM) CEO Christian Hogg on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-01 18:33 EST | News | Hutchmed gets approval to market Elunate for colorectal cancer in Macau | N/A | |
| 2022-02-04 14:38 EST | News | Hutchmed begins 1b/2 study of HMPL-453 combo to treat solid tumors in China | N/A | |
| 2022-01-20 13:45 EST | News | Hutchmed begins phase 1 trial of HMPL-653 to treat solid tumors in China | N/A | |
| 2022-01-12 15:59 EST | News | Hutchmed's HMPL-523 secures Breakthrough Therapy tag in China for immune thrombocytopenia | N/A | |
| 2021-12-06 08:27 EST | News | Hutchmed completes enrollment of Phase III fruquintinib trial in colorectal cancer | N/A | |
| 2021-11-24 11:14 EST | News | Hutchmed, AstraZeneca launch Phase III Orpathys + Tagrisso combo study in China in lung cancer | N/A | |
| 2021-10-28 11:27 EST | News | HUTCHMED initiates late-stage HMPL-523 autoimmune disorder study | N/A | |
| 2021-09-22 16:23 EST | News | Hutchmed nabs Breakthrough Therapy status for amdizalisib in China | N/A | |
| 2021-09-22 16:21 EST | News | Hutchmed initiates surufatinib study in Japan for advanced neuroendocrine tumors | N/A | |
| 2021-09-22 16:21 EST | News | Hutchmed launches late-stage surufatinib + toripalimab trial in China for neuroendocrine carcinoma | N/A | |
| 2021-09-08 21:20 EST | News | Hutchmed, AstraZeneca launch Orpathys/Tagrisso combo lung cancer trial in China | N/A | |
| 2021-08-26 05:50 EST | News | Hutchmed initiates mid-stage fruquintinib combo study in breast or endometrial cancer | N/A | |
| 2021-08-09 00:55 EST | News | Hutchmed inks Tazverik development deal with Epizyme in Greater China | N/A | |
| 2021-08-04 20:51 EST | News | HUTCHMED (China) Limited (HCM) CEO Christian Hogg on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-28 15:10 EST | News | Hutchison China MediTech EPS beats by $0.34, beats on revenue | N/A | |
| 2021-07-28 15:10 EST | News | Hutchmed shares rise after HY results | N/A | |
| 2021-07-22 14:46 EST | News | Innovent Bio, Hutchmed's Tyvyt + Fruquintinib show promising action in colorectal cancer study | N/A | |
About Hutchison China MediTech Limited (HCM):
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It offers research and development services; and manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma and soft tissue sarcoma, neuroendocrine neoplasms, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. Hutchison China MediTech Limited has collaboration agreement with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., and Shanghai Junshi Biosciences Co. Ltd. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
General
- Name Hutchison China MediTech Limited
- Symbol HCM
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 1,280
- Last Split Factor1:1
- Last Split Date2019-05-30
- Fiscal Year EndDecember
- IPO Date2016-03-17
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.hutch-med.com
View More
Valuation
- Trailing PE 17.69
- Price/Sales (Trailing 12 Mt.) 16.56
- Price/Book (Most Recent Quarter) 8.13
- Enterprise Value Revenue 15.54
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -55%
- Operating Margin -86%
- Return on Assets -21%
- Return on Equity -28%
- Revenue 227.98 million
- Earnings Per Share -$0.66
- Revenue Per Share $1.64
- Gross Profit -135319000
- Quarterly Earnings Growth 13.6%
View More
Highlights
- Market Capitalization 4 billion
- EBITDA -106662000
- Analyst Target Price $40.01
- Book Value Per Share $3.34
View More
Share Statistics
- Shares Outstanding 145.54 million
- Shares Float 67.86 million
- % Held by Insiders 626%
- % Held by Institutions 33.78%
- Shares Short 773638
- Shares Short Prior Month 889580
- Short Ratio 3.21
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 0.58
- 52 Week High $37
- 52 Week Low $15.74
- 50 Day Moving Average 31.7
- 200 Day Moving Average 31.89
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Hutchison China MediTech Limited (HCM) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Hutchison China MediTech Limited (HCM) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2019-12-31 | 2020-03-03 | $53.34 million | -$0.25 | -$0.23 | -8.7% |
| 2019-09-30 | 2019-11-15 | $49.35 million | -$0.20 | -$0.17 | -17.65% |
| 2019-06-30 | 2019-07-30 | $50.03 million | -$0.04 | -$0.14 | 71.31% |
| 2019-03-31 | 2019-06-06 | $52.17 million | -$0.03 | -$0.13 | 76.92% |
| 2018-06-30 | 2018-07-27 | $51.09 million | -$0.47 | -$0.07 | -571.43% |
| 2017-06-30 | 2017-07-31 | $126.58 million | $0.01 | $0.07 | -85.71% |
Hutchison China MediTech Limited (HCM) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Hutchison China MediTech Limited (HCM) Chart:
Hutchison China MediTech Limited (HCM) News:
Below you will find a list of latest news for Hutchison China MediTech Limited (HCM) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Hutchison China MediTech Limited (HCM) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0 | CALL | 0 | 0 | 656.54 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | CALL | 0 | 0 | 489.82 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 342.76 | TRUE | 0 | 0 |
| 2024-05-17 | 10 | 0 | CALL | 0 | 0 | 208.62 | TRUE | 0 | 0 |
| 2024-05-17 | 12.5 | 5.6 | CALL | 0 | 1 | 145.35 | TRUE | 0 | 0 |
| 2024-05-17 | 15 | 2.4 | CALL | 0 | 16 | 99.21 | TRUE | 0 | 0 |
| 2024-05-17 | 17.5 | 0.95 | CALL | 10 | 7 | 67.35 | FALSE | 0.95 | 0 |
| 2024-05-17 | 20 | 0.35 | CALL | 51 | 7 | 71.83 | FALSE | 0.35 | 0 |
| 2024-05-17 | 22.5 | 0.52 | CALL | 0 | 3 | 102.65 | FALSE | 0 | 0 |
| 2024-05-17 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 30 | 0.8 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 35 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 10 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 12.5 | 1 | PUT | 0 | 10 | 117.63 | FALSE | 0 | 0 |
| 2024-05-17 | 15 | 0.8 | PUT | 0 | 6 | 98.55 | FALSE | 0 | 0 |
| 2024-05-17 | 17.5 | 1.8 | PUT | 0 | 13 | 84.45 | TRUE | 0 | 0 |
| 2024-05-17 | 20 | 0 | PUT | 0 | 0 | 134.51 | TRUE | 0 | 0 |
| 2024-05-17 | 22.5 | 0 | PUT | 0 | 0 | 128.77 | TRUE | 0 | 0 |
| 2024-05-17 | 25 | 0 | PUT | 0 | 0 | 118.5 | TRUE | 0 | 0 |
| 2024-05-17 | 30 | 0 | PUT | 0 | 0 | 172.72 | TRUE | 0 | 0 |
| 2024-05-17 | 35 | 0 | PUT | 0 | 0 | 283.71 | TRUE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | CALL | 0 | 0 | 1353.61 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 0 | CALL | 0 | 0 | 226.15 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | CALL | 0 | 0 | 349.94 | TRUE | 0 | 0 |
| 2024-06-21 | 10 | 0 | CALL | 0 | 0 | 255.08 | TRUE | 0 | 0 |
| 2024-06-21 | 12.5 | 0 | CALL | 0 | 0 | 79.58 | TRUE | 0 | 0 |
| 2024-06-21 | 15 | 0 | CALL | 0 | 0 | 79.72 | TRUE | 0 | 0 |
| 2024-06-21 | 17.5 | 1.95 | CALL | 1 | 0 | 78.4 | FALSE | 1.95 | 0 |
| 2024-06-21 | 20 | 0 | CALL | 0 | 0 | 129.5 | FALSE | 0 | 0 |
| 2024-06-21 | 22.5 | 0 | CALL | 0 | 0 | 154.59 | FALSE | 0 | 0 |
| 2024-06-21 | 25 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 30 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 10 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 12.5 | 0 | PUT | 0 | 0 | 187.04 | FALSE | 0 | 0 |
| 2024-06-21 | 15 | 0 | PUT | 0 | 0 | 136.28 | FALSE | 0 | 0 |
| 2024-06-21 | 17.5 | 0 | PUT | 0 | 0 | 90.62 | TRUE | 0 | 0 |
| 2024-06-21 | 20 | 0 | PUT | 0 | 0 | 53.27 | TRUE | 0 | 0 |
| 2024-06-21 | 22.5 | 0 | PUT | 0 | 0 | 70.53 | TRUE | 0 | 0 |
| 2024-06-21 | 25 | 0 | PUT | 0 | 0 | 68.47 | TRUE | 0 | 0 |
| 2024-06-21 | 30 | 0 | PUT | 0 | 0 | 207.06 | TRUE | 0 | 0 |
| 2024-08-16 | 2.5 | 0 | CALL | 0 | 0 | 351.38 | TRUE | 0 | 0 |
| 2024-08-16 | 5 | 0 | CALL | 0 | 0 | 219.57 | TRUE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | CALL | 0 | 0 | 158.63 | TRUE | 0 | 0 |
| 2024-08-16 | 10 | 0 | CALL | 0 | 0 | 65.08 | TRUE | 0 | 0 |
| 2024-08-16 | 12.5 | 7.32 | CALL | 0 | 0 | 84.37 | TRUE | 0 | 0 |
| 2024-08-16 | 15 | 4.4 | CALL | 0 | 4 | 68 | TRUE | 0 | 0 |
| 2024-08-16 | 17.5 | 5.9 | CALL | 0 | 17 | 74.55 | FALSE | 0 | 0 |
| 2024-08-16 | 20 | 1.96 | CALL | 0 | 5 | 64.22 | FALSE | 0 | 0 |
| 2024-08-16 | 22.5 | 2.32 | CALL | 0 | 5 | 66.58 | FALSE | 0 | 0 |
| 2024-08-16 | 25 | 0 | CALL | 0 | 0 | 74.94 | FALSE | 0 | 0 |
| 2024-08-16 | 30 | 0.65 | CALL | 0 | 1 | 86.62 | FALSE | 0 | 0 |
| 2024-08-16 | 35 | 0.65 | CALL | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 7.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-08-16 | 10 | 0.55 | PUT | 0 | 1 | 105.47 | FALSE | 0 | 0 |
| 2024-08-16 | 12.5 | 0 | PUT | 0 | 0 | 76.03 | FALSE | 0 | 0 |
| 2024-08-16 | 15 | 1.97 | PUT | 0 | 15 | 73.53 | FALSE | 0 | 0 |
| 2024-08-16 | 17.5 | 2.85 | PUT | 0 | 20 | 66.09 | TRUE | 0 | 0 |
| 2024-08-16 | 20 | 3.93 | PUT | 0 | 0 | 62.82 | TRUE | 0 | 0 |
| 2024-08-16 | 22.5 | 0 | PUT | 0 | 0 | 104.43 | TRUE | 0 | 0 |
| 2024-08-16 | 25 | 8.5 | PUT | 0 | 5 | 83.84 | TRUE | 0 | 0 |
| 2024-08-16 | 30 | 0 | PUT | 0 | 0 | 85.71 | TRUE | 0 | 0 |
| 2024-08-16 | 35 | 0 | PUT | 0 | 0 | 101.39 | TRUE | 0 | 0 |
| 2024-11-15 | 2.5 | 0 | CALL | 0 | 0 | 260.32 | TRUE | 0 | 0 |
| 2024-11-15 | 5 | 0 | CALL | 0 | 0 | 149.23 | TRUE | 0 | 0 |
| 2024-11-15 | 7.5 | 0 | CALL | 0 | 0 | 115 | TRUE | 0 | 0 |
| 2024-11-15 | 10 | 0 | CALL | 0 | 0 | 97.44 | TRUE | 0 | 0 |
| 2024-11-15 | 12.5 | 0 | CALL | 0 | 0 | 71.74 | TRUE | 0 | 0 |
| 2024-11-15 | 15 | 5.2 | CALL | 0 | 5 | 53.46 | TRUE | 0 | 0 |
| 2024-11-15 | 17.5 | 0 | CALL | 0 | 0 | 69.51 | FALSE | 0 | 0 |
| 2024-11-15 | 20 | 0 | CALL | 0 | 0 | 65.87 | FALSE | 0 | 0 |
| 2024-11-15 | 22.5 | 2.15 | CALL | 0 | 5 | 67.03 | FALSE | 0 | 0 |
| 2024-11-15 | 25 | 0 | CALL | 0 | 0 | 72.37 | FALSE | 0 | 0 |
| 2024-11-15 | 30 | 0 | CALL | 0 | 0 | 68.66 | FALSE | 0 | 0 |
| 2024-11-15 | 35 | 0.5 | CALL | 0 | 3 | 83.28 | FALSE | 0 | 0 |
| 2024-11-15 | 2.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 7.5 | 1.84 | PUT | 0 | 2 | 0 | FALSE | 0 | 0 |
| 2024-11-15 | 10 | 2.14 | PUT | 0 | 2 | 88.1 | FALSE | 0 | 0 |
| 2024-11-15 | 12.5 | 1.35 | PUT | 0 | 5 | 70.97 | FALSE | 0 | 0 |
| 2024-11-15 | 15 | 2.3 | PUT | 0 | 5 | 72.05 | FALSE | 0 | 0 |
| 2024-11-15 | 17.5 | 0 | PUT | 0 | 0 | 69.64 | TRUE | 0 | 0 |
| 2024-11-15 | 20 | 4.7 | PUT | 0 | 5 | 65.74 | TRUE | 0 | 0 |
| 2024-11-15 | 22.5 | 0 | PUT | 0 | 0 | 66.88 | TRUE | 0 | 0 |
| 2024-11-15 | 25 | 0 | PUT | 0 | 0 | 75.53 | TRUE | 0 | 0 |
| 2024-11-15 | 30 | 0 | PUT | 0 | 0 | 76.63 | TRUE | 0 | 0 |
| 2024-11-15 | 35 | 0 | PUT | 0 | 0 | 83.44 | TRUE | 0 | 0 |
Latest HCM Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 200 | $9.505 |
| Jun 13, 2022 7:59 PM EST | 290 | $9.5 |
| Jun 13, 2022 7:59 PM EST | 17 | $9.505 |
| Jun 13, 2022 7:59 PM EST | 40 | $9.5 |
| Jun 13, 2022 7:59 PM EST | 38 | $9.5 |
Hutchison China MediTech Limited (HCM) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000060/0001648257-20-000060-index.htm |
| 2019-12-31 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1648257/000000000019016879/0000000000-19-016879-index.htm |
| 2020-02-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1648257/000000000020001316/0000000000-20-001316-index.htm |
| 2020-03-19 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1648257/000000000020002464/0000000000-20-002464-index.htm |
| 2020-07-06 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1648257/000095014220001696/0000950142-20-001696-index.htm |
| 2019-07-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000104746919004438/0001047469-19-004438-index.htm |
| 2019-09-30 | 424B7 | Prospectus [Rule 424(b)(7)] | https://www.sec.gov/Archives/edgar/data/1648257/000104746919005512/0001047469-19-005512-index.htm |
| 2019-09-30 | 424B7 | Prospectus [Rule 424(b)(7)] | https://www.sec.gov/Archives/edgar/data/1648257/000104746919005517/0001047469-19-005517-index.htm |
| 2020-01-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000104746920000340/0001047469-20-000340-index.htm |
| 2020-01-21 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1648257/000104746920000354/0001047469-20-000354-index.htm |
| 2020-01-23 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1648257/000104746920000432/0001047469-20-000432-index.htm |
| 2020-04-06 | F-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1648257/000104746920002085/0001047469-20-002085-index.htm |
| 2019-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000110465919051893/0001104659-19-051893-index.htm |
| 2019-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000110465919051910/0001104659-19-051910-index.htm |
| 2019-09-30 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1648257/000110465919051916/0001104659-19-051916-index.htm |
| 2019-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000110465919051936/0001104659-19-051936-index.htm |
| 2019-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000110465919052046/0001104659-19-052046-index.htm |
| 2019-09-30 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1648257/000110465919052050/0001104659-19-052050-index.htm |
| 2020-01-15 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1648257/000110465920004125/0001104659-20-004125-index.htm |
| 2020-01-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000110465920005674/0001104659-20-005674-index.htm |
| 2020-01-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000110465920006056/0001104659-20-006056-index.htm |
| 2020-01-29 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1648257/000110465920007809/0001104659-20-007809-index.htm |
| 2020-02-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000110465920011574/0001104659-20-011574-index.htm |
| 2020-02-21 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1648257/000110465920023624/0001104659-20-023624-index.htm |
| 2020-03-03 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1648257/000110465920028220/0001104659-20-028220-index.htm |
| 2020-03-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000110465920028221/0001104659-20-028221-index.htm |
| 2020-04-29 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1648257/000110465920052824/0001104659-20-052824-index.htm |
| 2020-07-07 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1648257/000110465920081527/0001104659-20-081527-index.htm |
| 2020-07-30 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1648257/000110465920088038/0001104659-20-088038-index.htm |
| 2020-07-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000110465920088202/0001104659-20-088202-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1648257/000156223020000031/0001562230-20-000031-index.htm |
| 2019-08-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000063/0001648257-19-000063-index.htm |
| 2019-08-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000067/0001648257-19-000067-index.htm |
| 2019-08-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000069/0001648257-19-000069-index.htm |
| 2019-09-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000071/0001648257-19-000071-index.htm |
| 2019-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000073/0001648257-19-000073-index.htm |
| 2019-09-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000079/0001648257-19-000079-index.htm |
| 2019-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000081/0001648257-19-000081-index.htm |
| 2019-10-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000083/0001648257-19-000083-index.htm |
| 2019-10-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000085/0001648257-19-000085-index.htm |
| 2019-10-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000088/0001648257-19-000088-index.htm |
| 2019-10-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000090/0001648257-19-000090-index.htm |
| 2019-11-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000093/0001648257-19-000093-index.htm |
| 2019-11-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000095/0001648257-19-000095-index.htm |
| 2019-11-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000097/0001648257-19-000097-index.htm |
| 2019-12-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000100/0001648257-19-000100-index.htm |
| 2019-12-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000102/0001648257-19-000102-index.htm |
| 2019-12-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825719000105/0001648257-19-000105-index.htm |
| 2020-01-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000002/0001648257-20-000002-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000004/0001648257-20-000004-index.htm |
| 2020-01-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000006/0001648257-20-000006-index.htm |
| 2020-01-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000008/0001648257-20-000008-index.htm |
| 2020-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000010/0001648257-20-000010-index.htm |
| 2020-02-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000012/0001648257-20-000012-index.htm |
| 2020-02-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000014/0001648257-20-000014-index.htm |
| 2020-03-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000017/0001648257-20-000017-index.htm |
| 2020-03-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000021/0001648257-20-000021-index.htm |
| 2020-03-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000023/0001648257-20-000023-index.htm |
| 2020-04-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000026/0001648257-20-000026-index.htm |
| 2020-04-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000028/0001648257-20-000028-index.htm |
| 2020-04-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000031/0001648257-20-000031-index.htm |
| 2020-04-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000034/0001648257-20-000034-index.htm |
| 2020-04-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000036/0001648257-20-000036-index.htm |
| 2020-05-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000039/0001648257-20-000039-index.htm |
| 2020-05-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000041/0001648257-20-000041-index.htm |
| 2020-05-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000043/0001648257-20-000043-index.htm |
| 2020-05-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000046/0001648257-20-000046-index.htm |
| 2020-06-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000048/0001648257-20-000048-index.htm |
| 2020-06-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000050/0001648257-20-000050-index.htm |
| 2020-06-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000052/0001648257-20-000052-index.htm |
| 2020-06-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000054/0001648257-20-000054-index.htm |
| 2020-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000056/0001648257-20-000056-index.htm |
| 2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000058/0001648257-20-000058-index.htm |
| 2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000060/0001648257-20-000060-index.htm |
| 2020-07-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000062/0001648257-20-000062-index.htm |
| 2020-07-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000064/0001648257-20-000064-index.htm |
| 2020-07-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000067/0001648257-20-000067-index.htm |
| 2020-07-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000069/0001648257-20-000069-index.htm |
| 2020-07-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000072/0001648257-20-000072-index.htm |
| 2020-08-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000074/0001648257-20-000074-index.htm |
| 2020-08-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000076/0001648257-20-000076-index.htm |
| 2020-08-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000078/0001648257-20-000078-index.htm |
| 2020-08-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000080/0001648257-20-000080-index.htm |
| 2020-09-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000085/0001648257-20-000085-index.htm |
| 2020-09-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000087/0001648257-20-000087-index.htm |
| 2020-09-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000089/0001648257-20-000089-index.htm |
| 2020-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000091/0001648257-20-000091-index.htm |
| 2020-09-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000093/0001648257-20-000093-index.htm |
| 2020-10-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000099/0001648257-20-000099-index.htm |
| 2020-10-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000101/0001648257-20-000101-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1648257/000164825720000103/0001648257-20-000103-index.htm |
| 2020-03-06 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1648257/999999999720001147/9999999997-20-001147-index.htm |